Guidance document: management priorities in salicylate toxicity.

Article Details

Citation

Copy to clipboard

Authors unspecified

Guidance document: management priorities in salicylate toxicity.

J Med Toxicol. 2015 Mar;11(1):149-52. doi: 10.1007/s13181-013-0362-3.

PubMed ID

25715929 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drugs

Acetylsalicylic acid

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Bismuth subsalicylate Aminosalicylic acid	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Bismuth subsalicylate.
Bismuth subsalicylate Salicylic acid	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Salicylic acid is combined with Bismuth subsalicylate.
Bismuth subsalicylate Olsalazine	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Olsalazine is combined with Bismuth subsalicylate.
Bismuth subsalicylate Mesalazine	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Mesalazine is combined with Bismuth subsalicylate.
Choline salicylate Aminosalicylic acid	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Choline salicylate.